Anthem Biosciences IPO Day 1: Check GMP, Subscription Status & Key Highlights
Anthem Biosciences is a leading Indian Contract Research, Development & Manufacturing Organization (CRDMO). The company has launched its IPO today on July 14, 2025. The bidding window for Anthem Biosciences IPO will be open for public subscription until July 16, 2025. The allotment process is expected to be finalised on Thursday, July 17, 2025. Anthem Biosciences IPO will be listed on BSE and NSE, with a tentative listing date fixed as Monday, July 21, 2025.
Anthem Biosciences IPO Details
The total issue size of the Anthem Biosciences IPO is ₹3,395.00 crores. The issue is entirely an offer for sale of 5.96 crore shares. The issue price band is set at ₹540 – ₹570 per share. The minimum lot size of the issue is 26, and one can apply with a minimum investment of ₹14,040.
JM Financial Limited, Citigroup Global Markets India, J P Morgan India and Nomura Financial Advisory and Securities (India) Pvt Ltd are the book-running lead managers of the Anthem Biosciences IPO, while Kfin Technologies Limited is the registrar for the issue.
Anthem Biosciences Day 1 Subscription Status
(July 14, 2025, 5 PM)
On Day 1, Anthem Biosciences IPO was subscribed 0.77 times. The public issue was subscribed 0.62 times in the retail category, 0.39 times in QIB, and 1.64 times in the NII category.
Utilisation of Proceeds
The Company will not receive any proceeds from the Offer and all the Offer Proceeds will be received by the Promoter Selling Shareholder after deduction of Offer related expenses and relevant taxes thereon, to be borne by the Promoter Selling Shareholder.
Click here to explore other Upcoming IPOs
GMP Details
According to Business Standard, the Grey Market Premium (GMP) of Anthem Biosciences Limited stood at ₹100 as of July 14, 2025, 8:20 a.m. This indicates that the estimated listing price of the shares can be around ₹670, based on the upper end of the price band at ₹570. The expected gain per share is 17.5%.
|
Source: Business Standard Media Report dated July 14, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Click here to check out newly Listed IPOs
About Anthem Biosciences Limited
Anthem Biosciences, founded in 2006 and headquartered in Bengaluru, is a leading Indian Contract Research, Development & Manufacturing Organization (CRDMO). It offers end-to-end services across drug discovery, development, and manufacturing for both small molecules and biologics. The company serves over 550 clients across 44 countries, with major contributions from regulated markets like the US, Europe, and Japan.
In FY25, Anthem reported a revenue of ₹1,844.6 crore and a net profit of ₹451.3 crore.
|
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory. To read the RA disclaimer, please click here |